Gelesis Holdings Total Liabilities 2021-2022 | GLS

Gelesis Holdings total liabilities from 2021 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
Gelesis Holdings Annual Total Liabilities
(Millions of US $)
2021 $330
2020 $317
2019 $
Gelesis Holdings Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $143
2021-12-31 $476
2021-09-30 $321
2021-06-30 $272
2021-03-31 $272
2020-12-31
2020-09-30 $272
2020-06-30 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.114B $0.011B
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00